Promyelocytic leukemia protein induces apoptosis due to caspase-8 activation via the repression of NFkappaB activation in glioblastoma.

Promyelocytic leukemia (PML) protein plays an essential role in the induction of apoptosis; its expression is reduced in various cancers. As the functional roles of PML in glioblastoma multiforme (GBM) have not been clarified, we assessed the expression of PML protein in GBM tissues and explored the mechanisms of PML-regulated cell death in GBM cells. We examined the PML mRNA level and the expression of PML protein in surgical GBM specimens. PML-regulated apoptotic mechanisms in GBM cells transfected with plasmids expressing the PML gene were examined. The protein expression of PML was significantly lower in GBM than in non-neoplastic tissues; approximately 10% of GBM tissues were PML-null. The PML mRNA levels were similar in both tissue types. The overexpression of PML activated caspase-8 and induced apoptosis in GBM cells. In these cells, PML decreased the expression of transactivated forms of NFkappaB/p65, and c-FLIP gene expression was suppressed. Therefore, PML-induced apoptosis resulted from the suppression of the transcriptional activity of NFkappaB/p65. PML overexpression decreased phosphorylated IkappaBalpha and nuclear NFkappaB/p65 and increased the expression of the suppressor of cytokine signaling (SOCS-1). A proteasome inhibitor blocked the reduction of activated p65 by PML. The reduction of PML is associated with the pathogenesis of GBM. PML induces caspase-8-dependent apoptosis via the repression of NFkappaB activation by which PML facilitates the proteasomal degradation of activated p65 and the sequestration of p65 with IkappaBalpha in the cytoplasm. This novel mechanism of PML-regulated apoptosis may represent a therapeutic target for GBM.

[1]  H. Lee,et al.  Loss of promyelocytic leukemia protein in human gastric cancers. , 2007, Cancer letters.

[2]  Xin-yang Wang,et al.  Overexpression of PML induced apoptosis in bladder cancer cell by caspase dependent pathway. , 2006, Cancer letters.

[3]  T. Kumanishi,et al.  Inhibition of Cellular Proliferation and Induction of Apoptosis by Curcumin in Human Malignant Astrocytoma Cell Lines , 2005, Journal of Neuro-Oncology.

[4]  H. Ohgaki,et al.  Genetic pathways to glioblastomas , 2005, Neuropathology : official journal of the Japanese Society of Neuropathology.

[5]  P. Black,et al.  In vitro and In vivo Activity of the Nuclear Factor-κB Inhibitor Sulfasalazine in Human Glioblastomas , 2004, Clinical Cancer Research.

[6]  P. Pandolfi,et al.  Loss of the tumor suppressor PML in human cancers of multiple histologic origins. , 2004, Journal of the National Cancer Institute.

[7]  A. Ryo,et al.  Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. , 2003, Molecular cell.

[8]  P. Pandolfi,et al.  Promyelocytic Leukemia Protein Sensitizes Tumor Necrosis Factor α-Induced Apoptosis by Inhibiting the NF-κB Survival Pathway* , 2003, The Journal of Biological Chemistry.

[9]  Margaret Wrensch,et al.  Molecular epidemiology of glioblastoma. , 2003, Cancer journal.

[10]  M. Nakao,et al.  PML‐nuclear bodies are involved in cellular serum response , 2003, Genes to cells : devoted to molecular & cellular mechanisms.

[11]  Zhi-xiang Xu,et al.  The Promyelocytic Leukemia Protein Represses A20-mediated Transcription* , 2002, The Journal of Biological Chemistry.

[12]  M. Knowling,et al.  Concurrent Modified PCV Chemotherapy and Radiotherapy in Newly Diagnosed Grade IV Astrocytoma , 2002, Journal of Neuro-Oncology.

[13]  T. Kumanishi,et al.  Aberrant nuclear factor-kappaB activity and its participation in the growth of human malignant astrocytoma. , 2002, Journal of neurosurgery.

[14]  W. Alexander,et al.  The SOCS box: a tale of destruction and degradation. , 2002, Trends in biochemical sciences.

[15]  G. Stark,et al.  Distinct Roles of the IκB Kinase α and β Subunits in Liberating Nuclear Factor κB (NF-κB) from IκB and in Phosphorylating the p65 Subunit of NF-κB* , 2001, The Journal of Biological Chemistry.

[16]  R. Evans,et al.  Transcriptional regulation in acute promyelocytic leukemia , 2001, Oncogene.

[17]  N. Ellis,et al.  Regulation and Localization of the Bloom Syndrome Protein in Response to DNA Damage , 2001, The Journal of cell biology.

[18]  P. Pandolfi.  Oncogenes and tumor suppressors in the molecular pathogenesis of acute promyelocytic leukemia. , 2001, Human molecular genetics.

[19]  P. Pearson,et al.  Atmospheric carbon dioxide concentrations over the past 60 million years , 2000, Nature.

[20]  S. Lowe,et al.  PML is induced by oncogenic ras and promotes premature senescence. , 2000, Genes & development.

[21]  Pier Paolo Pandolfi,et al.  PML regulates p53 acetylation and premature senescence induced by oncogenic Ras , 2000, Nature.

[22]  Pier Paolo Pandolfi,et al.  The transcriptional role of PML and the nuclear body , 2000, Nature Cell Biology.

[23]  P. Pandolfi,et al.  A role for PML and the nuclear body in genomic stability , 1999, Oncogene.

[24]  H. Sakurai,et al.  IκB Kinases Phosphorylate NF-κB p65 Subunit on Serine 536 in the Transactivation Domain* , 1999, The Journal of Biological Chemistry.

[25]  R. Reddel,et al.  Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. , 1999, Cancer research.

[26]  T. Gilliam,et al.  Differential SMN2 expression associated with SMA severity , 1998, Nature Genetics.

[27]  M. Koken,et al.  PML induces a novel caspase-independent death process , 1998, Nature Genetics.

[28]  P. Pandolfi,et al.  Pml is essential for multiple apoptotic pathways , 1998, Nature Genetics.

[29]  P. Johnson,et al.  Altered expression of the growth and transformation suppressor PML gene in human hepatocellular carcinomas and in hepatitis tissues. , 1998, European journal of cancer.

[30]  G. Maul,et al.  A novel nuclear substructure, ND10: distribution in normal and neoplastic human tissues. , 1998, International journal of molecular medicine.

[31]  P. Pandolfi,et al.  Role of PML in cell growth and the retinoic acid pathway. , 1998, Science.

[32]  Margot Thome,et al.  Inhibition of death receptor signals by cellular FLIP , 1997, Nature.

[33]  S. Pileri,et al.  Heterogeneous nuclear expression of the promyelocytic leukemia (PML) protein in normal and neoplastic human tissues. , 1996, The American journal of pathology.

[34]  David Baltimore,et al.  Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB , 1995, Nature.

[35]  J. Sobczak-Thépot,et al.  The PML growth-suppressor has an altered expression in human oncogenesis. , 1995, Oncogene.

[36]  P. Graham.  Meta‐analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults , 1993, Cancer.

[37]  Christine Chomienne,et al.  The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR , 1991, Cell.

[38]  S. Green,et al.  Glioblastoma multiforme and anaplastic astrocytoma pathologic criteria and prognostic implications , 1985, Cancer.

[39]  M. Karin.  Nuclear factor-kappaB in cancer development and progression. , 2006, Nature.

[40]  E. Choi,et al.  Promyelocytic leukemia protein-induced growth suppression and cell death in liver cancer cells , 2005, Cancer Gene Therapy.

[41]  P. Pandolfi,et al.  Promyelocytic leukemia protein sensitizes tumor necrosis factor alpha-induced apoptosis by inhibiting the NF-kappaB survival pathway. , 2003, The Journal of biological chemistry.

[42]  G. Stark,et al.  Distinct roles of the Ikappa B kinase alpha and beta subunits in liberating nuclear factor kappa B (NF-kappa B) from Ikappa B and in phosphorylating the p65 subunit of NF-kappa B. , 2002, The Journal of biological chemistry.

[43]  H. Sakurai,et al.  IkappaB kinases phosphorylate NF-kappaB p65 subunit on serine 536 in the transactivation domain. , 1999, The Journal of biological chemistry.

[44]  H. Pahl,et al.  Activators and target genes of Rel/NF-kappaB transcription factors. , 1999, Oncogene.

[45]  E. Hedley‐Whyte,et al.  Correlates of survival and the Daumas-Duport grading system for astrocytomas. , 1991, Journal of neurosurgery.